Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.70 |
| ▸ | ABL1 | P00519 | 9/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.70 |
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | LCK | P06239 | 2/20 | 0.70 |
| ▸ | FYN | P06241 | 2/20 | 0.70 |
| ▸ | YES1 | P07947 | 2/20 | 0.70 |
| ▸ | LYN | P07948 | 2/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.70 |
| ▸ | PRKACA | P17612 | 2/20 | 0.70 |
| ▸ | FRK | P42685 | 2/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.70 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.70 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.70 |
| ▸ | BLK | P51451 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14617301 | 0.87 | SRC (0.89) | SRCABL1HTTEGFRKDR | |
| SCHEMBL3609175 | 0.86 | SRC (0.69) | SRCABL1HTTEGFRKDR | |
| SCHEMBL1319408 | 0.84 | NUDT14 (0.59) | SRCABL1HTTEGFRKDR | |
| SCHEMBL409444 | 0.83 | SRC (0.82) | SRCABL1HTTEGFRKDR | |
| SCHEMBL407934 | 0.82 | SRC (1.00) | SRCABL1HTTEGFRKDR | |
| SCHEMBL29432587 | 0.82 | SRC (1.00) | SRCABL1HTTEGFRKDR | |
| SCHEMBL29355398 | 0.81 | SRC (1.00) | SRCABL1HTTEGFRKDR | |
| SCHEMBL1962682 | 0.81 | SRC (0.78) | SRCABL1HTTEGFRKDR | |
| SCHEMBL5620074 | 0.81 | SRC (0.78) | SRCABL1HTTEGFRKDR | |
| SCHEMBL3610160 | 0.81 | SRC (0.95) | SRCABL1HTTEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-2551270-A2 | PYRAZOLOPYRMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | The Regents of The University of California (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | SRC 218/4885ABL1 225/4885HTT 3111/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HTT 2147/4885 |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | TSLP, NLRP3, IL1B | SRC 3970/4885ABL1 2987/4885HTT 2116/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HTT 2147/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HTT 2147/4885 |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | TNF, TSLP, IL1B | SRC 3920/4885ABL1 2533/4885HTT 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.